chronic pain
Pain · 2012–2025
6decisions
5medicines
2carried consumer input
6individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| methadone Chronic severe disabling pain and severe disabling pain in palliative care patients where alternative pain management therapies have failed. | Jul 2025 | Recommended with restriction | 3 individuals |
| Secondary annual review of patients on ongoing treatment with PBS subsidised opioid medications for chronic pain. | Dec 2020 | Not recommended | no section in document |
| oxycodone hydrochloride + naloxone hydrochloride Chronic severe disabling pain unresponsive to non-narcotic analgesics. Three additional modified-release tablet strengths (2.5 mg/1.25 mg, 15 mg/7.5 mg, and 30… | Nov 2015 | Recommended | no section in document |
| oxycodone Chronic pain management in patients requiring long-term opioid therapy. This submission addresses the scheduling equivalence ('a' flagging) of generic… | Nov 2014 | Noted | 3 individuals Pharmaceutical Society · Australian Pain Society |
| tapentadol Chronic severe disabling pain not responding to non-narcotic analgesics. | Nov 2013 | Recommended with restriction | unclear |
| tapentadol Chronic severe disabling pain not responding to non-narcotic analgesics. | Mar 2012 | Not recommended | unclear |
Who spoke
Pharmaceutical Society · Australian Pain Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.